Literature DB >> 6591188

Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma.

R S Metzgar, N Rodriguez, O J Finn, M S Lan, V N Daasch, P D Fernsten, W C Meyers, W F Sindelar, R S Sandler, H F Seigler.   

Abstract

A competition radioimmunoassay was developed, utilizing a murine monoclonal antibody to human pancreatic adenocarcinoma cells. Immunoblotting of a standard antigen preparation from either serum or ascites fluid after electrophoresis in 1% agarose showed that the specific DU-PAN-2 activity resided in two major high molecular weight bands. DU-PAN-2 antigen levels were expressed as arbitrary units based on a standard partially purified antigen preparation. The inhibition curve with standard antigen was reproducible (SD less than 10%) and essentially linear from 25 to 200 units/ml. The mean DU-PAN-2 antigen concentration for the sera from 126 normal individuals was 81 units/ml. Sera from pediatric patients with malignancy had a mean of 127 units/ml, while nasopharyngeal, stage III melanoma, and ovarian carcinoma patients had means of 89, 92, and 119 units/ml, respectively. All values in normal subjects as well as the melanoma, nasopharyngeal, ovarian, and pediatric cancer patients were less than 400 units/ml. Intermediate antigen levels were detected in patients with alimentary tract malignancies. Eight of 20 gastric cancer and 8 of 76 colorectal carcinoma patients and 3 patients with benign or nonmalignant gastrointestinal tract disease had DU-PAN-2 values exceeding 400 units/ml. Ascites fluids from 6/6 and pancreatic juice from 2/2 pancreatic cancer patients had values greater than 750 units/ml. Serum from 68% of the 89 pancreatic cancer patients tested had DU-PAN-2 antigen levels greater than 400 units/ml. The mean serum value in this patient population was 4888 units/ml.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6591188      PMCID: PMC391674          DOI: 10.1073/pnas.81.16.5242

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  7 in total

1.  Gel electrophoresis of mucous glycoproteins. II. Effect of physical deaggregation and disulfide-bond cleavage.

Authors:  K G Holden; N C Yim; L J Griggs; J A Weisbach
Journal:  Biochemistry       Date:  1971-08-03       Impact factor: 3.162

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Monoclonal antibodies against human pancreatic adenocarcinoma: distribution of DU-PAN-2 antigen on glandular epithelia and adenocarcinomas.

Authors:  M J Borowitz; F L Tuck; W F Sindelar; P D Fernsten; R S Metzgar
Journal:  J Natl Cancer Inst       Date:  1984-05       Impact factor: 13.506

4.  Specific antigen in serum of patients with colon carcinoma.

Authors:  H Koprowski; M Herlyn; Z Steplewski; H F Sears
Journal:  Science       Date:  1981-04-03       Impact factor: 47.728

5.  Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin.

Authors:  J L Magnani; Z Steplewski; H Koprowski; V Ginsburg
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

6.  The separation and characterization of bronchial glycoproteins by density-gradient methods.

Authors:  J M Creeth; K R Bhaskar; J R Horton; I Das; M T Lopez-Vidriero; L Reid
Journal:  Biochem J       Date:  1977-12-01       Impact factor: 3.857

7.  Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies.

Authors:  R S Metzgar; M T Gaillard; S J Levine; F L Tuck; E H Bossen; M J Borowitz
Journal:  Cancer Res       Date:  1982-02       Impact factor: 12.701

  7 in total
  30 in total

1.  Determination of tumor marker levels in cystic fluid of benign liver cysts.

Authors:  K Iwase; H Takenaka; S Oshima; A Yagura; Y Nishimura; K Yoshidome; T Tanaka
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

Review 2.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

3.  Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

Authors:  T Kurihara; D E Brough; I Kovesdi; D W Kufe
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

4.  Expression of human tumor-associated antigens in pancreatic cancer induced in Syrian hamsters.

Authors:  Y Takiyama; H Egami; P M Pour
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

5.  Biosynthesis and secretion of mucin-related products in Hs746T gastric cancer cells.

Authors:  S Sano; K Okazaki; Y Yamamoto
Journal:  J Gastroenterol       Date:  1994-10       Impact factor: 7.527

6.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.

Authors:  D L Barnd; M S Lan; R S Metzgar; O J Finn
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

7.  Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody.

Authors:  D M Mahvi; W C Meyers; R C Bast; H F Seigler; R S Metzgar
Journal:  Ann Surg       Date:  1985-10       Impact factor: 12.969

Review 8.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

9.  Regulation of herpes simplex virus 1 replication using tumor-associated promoters.

Authors:  John T Mullen; Hideki Kasuya; Sam S Yoon; Nancy M Carroll; Timothy M Pawlik; Soundararajalu Chandrasekhar; Hideo Nakamura; James M Donahue; Kenneth K Tanabe
Journal:  Ann Surg       Date:  2002-10       Impact factor: 12.969

10.  Radioimmunodetection of human pancreatic tumor xenografts using DU-PAN II monoclonal antibody.

Authors:  K Nakamura; A Kubo; S Hashimoto; T Furuuchi; H Takami; O Abe
Journal:  Ann Nucl Med       Date:  1988-05       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.